Français

News

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

Today, September 30, Marks the Second National Day for Truth and Reconciliation in Canada

Today, September 30, Marks the Second National Day for Truth and Reconciliation in Canada

Crohn’s and Colitis Canada Awards 15 Post-Secondary Students a $5,000 Scholarship Through the 2022 AbbVie IBD Scholarship Program

Crohn’s and Colitis Canada Awards 15 Post-Secondary Students a $5,000 Scholarship Through the 2022 AbbVie IBD Scholarship Program

Inflammatory bowel disease researchers from across the country receive vital funding that supports projects investigating Crohn’s disease and ulcerative colitis

Inflammatory bowel disease researchers from across the country receive vital funding that supports projects investigating Crohn’s disease and ulcerative colitis

 5 6 7 8 9 10 11 12 13 14 

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest

Gutsy Walk
Camp Got 2 Go
Go Here
Volunteer